Will Assimini be covered by medical insurance in 2024? What is the latest reimbursement policy?

Asciminib (Asciminib) is a first-of-its-kind TKI that, unlike all other TKIs that inhibit ABL kinase activity in an ATP-competitive manner, binds to the myristoyl pocket of ABL1, inducing an inactive conformation of the kinase (specifically targeting the ABL myristoyl pocket or STAMP inhibitors). Aceminib offers several unique features with potential clinical significance that make it uniquely valuable. These include its activity against T315I and a unique resistance mutation pattern that is different from ATP-competing drugs.

The myristoyl pocket is present only in a limited number of kinases, allowing for higher selectivity. The unique binding site and complementary resistance mechanisms also offer the possibility of combination therapy with traditional TKIs, which have resulted in complete, durable remissions in animal models. These properties make aximinib an exciting new drug for clinical use. Aceminib is effective in most patients with severely pretreated chronic myelogenous leukemia and is a safe drug.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in the medical insurance. The original drug of Asiminib sold overseas is very expensive. The price of 20mg*60 oral tablets is about more than 20,000 US dollars, which is about 150,000 yuan in RMB. There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.